Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Company Overview

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $0.52 to $0.54
• 50-Day Range: $0.52 to $0.68
• 52-Week Range: $0.50 to $1.56
• Volume: 68,075 shs
• Average Volume: 166,689 shs
• Market Capitalization: $20.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Hold

Bolt Biotherapeutics Stock Analysis - MarketRank™

Bolt Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 481st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bolt Biotherapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bolt Biotherapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bolt Biotherapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Bolt Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bolt Biotherapeutics has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Bolt Biotherapeutics does not currently pay a dividend.

Dividend Growth

Bolt Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.47% of the float of Bolt Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bolt Biotherapeutics has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: N/A

News Sentiment

Bolt Biotherapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bolt Biotherapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BOLT Stock Analysis - Frequently Asked Questions

How have BOLT shares performed this year?

Bolt Biotherapeutics' stock was trading at $1.12 at the beginning of 2024. Since then, BOLT stock has decreased by 52.2% and is now trading at $0.5352.
View the best growth stocks for 2024 here.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its earnings results on Tuesday, November, 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04. The company earned $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative trailing twelve-month return on equity of 69.46%.

When did Bolt Biotherapeutics IPO?

Bolt Biotherapeutics (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' top institutional shareholders include Geode Capital Management LLC (0.92%) and FMR LLC (0.30%). Insiders that own company stock include Holdings A/S Novo, Edgar Engleman, Vivo Capital Viii, Llc and William P Quinn.
View institutional ownership trends.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BOLT
• CUSIP: 09769810
• CIK: 354655
• Web: www.boltbio.com
• Phone: 650-665-9295
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +554.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-69,200,000.00
• Net Margins: -665.56%
• Pretax Margin: -665.56%
• Return on Equity: -69.46%
• Return on Assets: -48.55%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 3.16
• Quick Ratio: 3.16

Sales & Book Value

• Annual Sales: $9.78 million
• Price / Sales: 2.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.97 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 38,273,000
• Free Float: 26,447,000
• Market Cap: $20.48 million
• Optionable: Not Optionable
• Beta: 0.93